EACA en es it fr

EACA Brand names, EACA Analogs

EACA Brand Names Mixture

  • No information avaliable

EACA Chemical_Formula


EACA RX_link


EACA fda sheet


EACA msds (material safety sheet)


EACA Synthesis Reference

No information avaliable

EACA Molecular Weight

131.173 g/mol

EACA Melting Point

205 oC

EACA H2O Solubility

5.05E+005 mg/L

EACA State




EACA Dosage Forms

Solution for injection (containing 250 mg/mL of aminocaproic acid) and tablets (500, 1000mg)

EACA Indication

For use in the treatment of excessive postoperative bleeding.

EACA Pharmacology

Aminocaproic acid works as an antifibrinolytic. It is a derivative of the amino acid lysine. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity.

EACA Absorption

Absorbed rapidly following oral administration. In adults, oral absorption appears to be a zero-order process with an absorption rate of 5.2 g/hr. The mean lag time in absorption is 10 minutes. After a single oral dose of 5 g, absorption was complete (F=1).

EACA side effects and Toxicity

A few cases of acute overdosage with intravenous administration have been reported. The effects have ranged from no reaction to transient hypotension to severe acute renal failure leading to death. The intravenous and oral LD50 were 3.0 and 12.0 g/kg respectively in the mouse and 3.2 and 16.4 g/kg respectively in the rat. An intravenous infusion dose of 2.3 g/kg was lethal in the dog.

EACA Patient Information

EACA Organisms Affected

Humans and other mammals